Afuresertib: an AKT inhibitor that “won its endpoint but lost on position”

Afuresertib’s origins are worth explaining first. It is an oral, ATP-competitive pan-AKT inhibitor that inhibits all three isoforms — AKT1, AKT2 and AKT3 — acting at a key downstream node of the PI3K/AKT/PTEN pathway. The molecule originated at GlaxoSmithKline, passed to Novartis in an asset swap in 2015, and in July 2018 Laekna obtained exclusive global rights to afuresertib (together with another molecule, uprosertib) from Novartis.

Laekna is a clinical-stage domestic biotech listed in Hong Kong under Chapter 18A (stock code 2105-B), with its R&D base in Shanghai; chairman and CEO Lu Xiangyang has an R&D background at multinationals such as Novartis, and its shareholders include OrbiMed, Shenzhen Capital Group and Novartis (holding shares from the 2018 deal). It has no marketed products and no commercial sales force — which makes it by nature a company that “completes the clinic and monetizes through deals”.

More critically, the company is visibly pivoting. Look at Laekna’s pipeline today and what is really in the spotlight is metabolism and weight loss: the ActRIIA/IIB antibody LAE102 (clinical collaboration with Lilly in November 2024), LAE103, LAE123, plus a string of metabolic targets such as amylin and apelin. Oncology assets (afuresertib, the CYP17 inhibitor LAE001, the PI3Kα mutant-selective LAE118, etc.) are still advancing, but internally their priority has clearly yielded to metabolism.

Setting competition aside and looking at demand first, the ground afuresertib stands on is not bad. China has about 350,000–400,000 new breast cancer cases a year, of which the HR+/HER2- subtype accounts for about 65%–70%, the largest segment. First-line standard of care for these patients is an aromatase inhibitor plus a CDK4/6 inhibitor (imported palbociclib, abemaciclib and ribociclib, and domestic dalpiciclib); once they progress to second and third line, treatment options become stretched.

That is exactly the position afuresertib targets: the second- to third-line population after CDK4/6 inhibitor treatment, with PIK3CA/AKT1/PTEN pathway alterations, in combination with fulvestrant. There is an epidemiological fact here favorable to local development — the PIK3CA mutation rate in Chinese HR+ breast cancer patients is about 43%–49%, clearly higher than the 30%–40% in Western populations. Adding AKT1 and PTEN alterations, the enriched population for this pathway is considerable, with a theoretically accessible population in the tens of thousands per year. And these patients are highly concentrated in leading cancer centers; the network of leading breast cancer PIs (Xu Binghe, Hu Xichun, Jiang Zefei, Shao Zhimin, Yuan Peng, Wang Shusen, Ma Fei, etc.) is mature, and AFFIRM-205 itself was run on this network.

Taking the real risks and opportunities of this asset apart, a few gates say the most.

If you only stare at the clinic, you will misread this drug. The main line of afuresertib’s value realization was never “Laekna selling it into a blockbuster itself”, but exchanging it for cash and milestones at the right moment. And Laekna has been quite deft at this.

On November 12, 2025, Laekna exclusively licensed the Greater China rights to afuresertib (LAE002) to Qilu Pharmaceutical. Two details easily written too narrowly need clarifying here: first, territory — the agreement explicitly defines “China region” as mainland China, Hong Kong, Macau and Taiwan, i.e. all of Greater China; second, scope — the license covers research, development and commercialization rights to the LAE002 molecule in Greater China, not limited to breast cancer (breast cancer is only the first indication; the phrase “until the first indication is approved in China” is the calculation point for milestone payments, not the boundary of rights). On economic terms: upfront plus clinical development milestones of up to RMB 530 million, total upfront and milestones of up to RMB 2.045 billion, plus tiered sales royalties from the low teens to the twenties in percent; Qilu is responsible for Greater China commercialization, and Laekna completes AFFIRM-205 and retains all rights outside Greater China.

This also explains why afuresertib’s “commercialization weakness” is not really a weakness: hospital access, channels, medical affairs and pharmacovigilance in Greater China are all taken on by a mature large pharma like Qilu; in these areas Laekna is not “weak” — it “simply doesn’t do them itself”. Its valuation is realized through a series of BD and registration milestones — the Qilu deal already landed is the first inflection point; next come milestone payments triggered by acceptance and approval of the marketing application; and after that, the rights outside Greater China still in its hands.

And the rights outside Greater China are precisely the most urgent and most uncertain move in this game. Globally, capivasertib has already been approved in the US, Europe and Japan, and hasn’t stopped at breast cancer — in June 2026 it won a new US indication in PTEN-deficient metastatic prostate cancer (based on CAPItello-281), with global development and commercialization still accelerating; Roche’s other AKT inhibitor, ipatasertib, has been discontinued globally. In other words, the AKT race overseas has been frozen into a landscape of “one winner charging ahead + one that has exited”. If afuresertib is to be licensed outside Greater China, buyers will certainly ask two things in due diligence: first, whether its China-dominated data package is sufficiently applicable for US and European regulators; second, as global second in class facing a rival expanding across multiple indications, how much differentiation room is left. The period right after a positive topline, before the overseas AKT window has been fully shut by capivasertib’s scale-up, is Laekna’s best — and possibly last — window to push an overseas license.

Put afuresertib back into the big picture of HR+/HER2- advanced breast cancer, and its position becomes clearer.

What it is fighting over is the main battlefield after CDK4/6 inhibitor resistance. As CDK4/6 inhibitor penetration in first line rises rapidly (especially after domestic dalpiciclib entered the NRDL), “how to manage resistance” after second line has become the most central clinical question in HR+ breast cancer. PI3K/AKT/PTEN pathway drugs are aimed precisely at this gap. But the problem is that this gap is now crowded with players: capivasertib (AKT) approved April 2025, inavolisib (PI3Kα) approved March 2025, alpelisib (PI3Kα) available through the Hainan Boao pilot program, and everolimus (mTOR) long in place. Afuresertib is the last to enter.

One of its real selling points is hidden in “elderly + oral”. About a third of Chinese patients with HR+ advanced breast cancer are over 65, and this population is better suited to oral once-daily regimens — compared with capivasertib’s intermittent dosing of “twice daily, four days on and three off”, afuresertib’s once daily is indeed simpler. But there is an unavoidable contradiction: in vitro, afuresertib inhibits metabolic enzymes and transporters such as CYP3A4, CYP2C8, OATP1B1 and BCRP, meaning it has clear interaction restrictions with many commonly used drugs, and elderly patients with multiple comorbidities taking several drugs at once are precisely the population at highest risk of interactions. Oral convenience and medication safety partly cancel each other out in the same group of people.

Compared with modalities such as ADCs and cell therapies that often get stuck on process scale-up and the cold chain, afuresertib, as an oral small-molecule tablet, is probably at its least worrying on the manufacturing side. It came from GSK and went through years of global early clinical work, so its synthesis and solid dosage routes are relatively mature; oral small molecules are usually stored at room temperature with no cold-chain pressure, and finished product cost as a share of price is far lower than for biologics, so margins should be enough to absorb the steep price cuts that come with NRDL entry for innovative drugs. It should be noted that these are reasonable inferences based on the oral small-molecule modality; there are no verifiable first-hand CMC materials on specific process details or cost structure; commercial manufacturing will most likely be handed to Qilu along with the Greater China rights, but the company has not disclosed specific progress on technology transfer.

What deserves more vigilance is the patent cliff. Afuresertib is an old molecule filed around 2008, and the remaining exclusivity on its core compound patent is likely short — a rough estimate from the public filing date puts it around the late 2020s to early 2030s, but this is only an estimate; the actual expiry must be based on the patent family registration at CNIPA and a formal freedom-to-operate (FTO) review. Once the core patent expires, as a structurally uncomplicated oral small molecule it will fairly quickly face domestic generics/consistency evaluation, with a limited exclusivity window; lifecycle management can only extend it through secondary patents such as new polymorphs, fixed-dose combinations and new indications — and this, stacked on the company’s stance of “treating oncology assets as cash cows and redirecting resources to weight loss”, compresses long-term upside.

First correct a number that is easy to use out of date: Laekna’s cash at the end of H1 2025 was about RMB 744 million, but by the end of 2025 cash and bank balances had recovered to about RMB 1.2 billion, and in 2025 the company recorded about RMB 107 million in revenue, mainly from the Qilu out-license. In other words, thanks to Qilu’s upfront and the cost-sharing on weight-loss assets from its 2024 collaboration with Lilly, Laekna’s books are actually more comfortable than those of many biotechs of the same size. For the afuresertib project alone, Greater China development and commercialization spending now sits mainly with Qilu, and Laekna itself barely burns money on it anymore. So the real constraint in this game was never money, but time and position.

On the timeline, several key nodes need to be timed precisely:

• August 2026: the marketing application has been accepted by CDE; what must be fought for next is review and approval speed — every month of delay widens the gap with capivasertib, already approved and on the NRDL.
• After the 2026 topline: push hard on out-licensing the rights outside China, while the overseas AKT window has not fully closed.
• Around 2027: the expected approval and NRDL negotiation window — but by then capivasertib will have completed its NRDL-driven scale-up, and afuresertib’s bargaining chips will be weaker, because it cannot produce head-to-head evidence against a reimbursed competitor.

Putting these three together, afuresertib’s value window is actually tight: it needs to complete both “marketing filing” and “ex-China licensing” before the rival’s NRDL-driven scale-up fully spreads. This is an endgame race against time.

Afuresertib is an intriguing sample. It proves one thing: in today’s crowded me-too environment, a gulf called “position” separates “clinical success” from “commercial success”. It won its own Phase 3 endpoint, yet in race position it had long since fallen a year behind capivasertib.

But looked at another way, Laekna has played this seemingly passive game quite well: locking in Qilu before the readout, retaining rights outside Greater China, staying asset-light in manufacturing, and pivoting the company’s main effort to weight loss — every step turns an asset “without a favorable position” into cash and options as efficiently as possible. For a biotech without commercial capability, recognizing that “this is a BD cash cow, not an in-house blockbuster” and then squeezing maximum value from it is itself a form of clear-headedness.

What to watch next for afuresertib is not whether it will be approved — on an HR of 0.33 it most likely will — but two more practical questions: once OS, response rates and complete safety data are unblinded, how much differentiation can they still support? And can the rights outside Greater China it holds be sold at a good price before the window of capivasertib’s global expansion closes? The answers will emerge over the next 12 to 18 months.